By Chris Wack

Synthorx Inc. (THOR) shares almost tripled to $68.05 in early trading after Sanofi SA (SAN.FR) said it was buying the clinical-stage biotechnology for $68 a share in cash.

The deal has an equity value of about $2.5 billion, and is expected to close in the first quarter of next year.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 09, 2019 10:13 ET (15:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Synthorx Charts.
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Synthorx Charts.